Due to the current crisis of COVID-19 pandemic in Thailand, the in-person conference is not allowed. The APBMT 2021 Organizing Committee has to organize the 26th Congress of Asia Pacific Blood and Marrow Transplantation (APBMT 2021) as a Virtual event.

Message from President

Dear friends and colleagues,
I hope this message will find you all well. I believe that we are all working very hard to get us through this difficult time during the last couple of years. Though the pandemic is very challenging, we have witnessed how great human endeavor against this pandemic can be. Many scientific achievements have been accomplished within record breaking time. And I believe that stem cell transplantation and cell therapy will benefit from these progresses as well.

It is an honor for The Thai Society of Hematology to be the host of Asia Pacific Blood and Marrow Transplantation (APBMT) Congress this year. The Congress will be held in Chiang Mai, Thailand on October 15-17, 2021. We will carry on the tradition of APBMT in promoting collaborative works in this region and around the world, together with bringing state of the arts education topics to the audience. The collaboration and experience sharing are at their best if we can meet on site. However, we are planning for this Conference as a hybrid meeting if the situation does not permit or international travelling cannot resume to normalcy.

I would like to cordially invite you to join us in the 26th APBMT Congress. Chiang Mai is a very beautiful and pleasant city. It has been a major tourist destination for several decades due to its charming culture and environment. It would be a great honor for us to welcome you there.
Sincerely,

Artit Ungkanont, M.D.
President, APBMT 2021

Meeting Room 1
Time Title
09.00-10.10
Session V: Hematologic malignancies during COVID-19 pandemic

แนะนำวิทยากร
นพ.วีระศักดิ์ นาวารวงศ์
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
Myeloma
นพ.เอกรัฐ รัฐฤทธิ์ธำรง
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
Lymphoma
พญ.ลัลธริมา ภู่พัฒน์
คณะแพทยศาสตร์ ม.ธรรมศาสตร์
Leukemia
นพ.กานดิษฎ์ ประยงค์รัตน์
กองอายุรกรรม โรงพยาบาลพระมงกุฎเกล้า
Q & A
นพ.วีระศักดิ์ นาวารวงศ์
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
นพ.เอกรัฐ รัฐฤทธิ์ธำรง
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
พญ.ลัลธริมา ภู่พัฒน์
คณะแพทยศาสตร์ ม.ธรรมศาสตร์
นพ.กานดิษฎ์ ประยงค์รัตน์
กองอายุรกรรม โรงพยาบาลพระมงกุฎเกล้า

10.10-10.30
Refreshment | Exhibition
10.30-11.40
Session VI: Hematology practice during COVID-19 pandemic

แนะนำวิทยากร
นพ.ปัญญา เสกสรรค์
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
ITP/Hemophilia
นพ.นัทธี นาคบุญนำ
คณะแพทยศาสตร์ศิริราชพยาบาล
Thalassemia
พญ.พชรพรรณ สุรพลชัย
คณะแพทยศาสตร์ โรงพยาบาลธรรมศาสตร์เฉลิมพระเกียรติ
Pediatric oncology
พญ.พรพรรณ ศรีพรสวรรค์
คณะแพทยศสตร์ ม.สงขลานครินทร์
Q & A 
นพ.ปัญญา เสกสรรค์
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
นพ.นัทธี นาคบุญนำ
คณะแพทยศาสตร์ศิริราชพยาบาล
พญ.พชรพรรณ สุรพลชัย
คณะแพทยศาสตร์ โรงพยาบาลธรรมศาสตร์เฉลิมพระเกียรติ
พญ.พรพรรณ ศรีพรสวรรค์
คณะแพทยศสตร์ ม.สงขลานครินทร์

11..40-12.40
Luncheon Symposium III: Takeda

แนะนำวิทยากร
นพ.สุภร จันท์จารุณี
คณะแพทยศาสตร์โรงพยาบาลรามาธิบดี
How proteosome inhibitor close the gap in relapsed/refractory multiple myeloma management: From clinical study and real-world evidence
พญ.ปณิสินี ลวสุต
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
Case series presentation
นพ.สุภร จันท์จารุณี
คณะแพทยศาสตร์โรงพยาบาลรามาธิบดี
Q & A
นพ.สุภร จันท์จารุณี
คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี
พญ.ปณิสินี ลวสุต
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

13.10-13.30
APBMT 2021

Opening Remark
Artit Ungkanont
Ramathibody Hospital, Mahidol University, Thailand

13.30-13.48
Presidential Symposium: Design the future of HCT Societies

•    Introduction
   
  Shinichiro Okamoto
      Keio University of Medicine, Japan
      Artit Ungkanont
      Ramathibody Hospital, Mahidol University, Thailand
•    EBMT perspective
     Nicolaus Kroger (Germany) (President of EBMT)

13.48-14.06
Presidential Symposium: Design the future of HCT Societies

•    ASTCT perspective
     Stella Davies (USA) (President of ASTCT)

14.06-14.24
Presidential Symposium: Design the future of HCT Societies

•    WBMT perspective
     Hildegard Greinix (Austria) (President of WBMT)

14.24-14.42
Presidential Symposium: Design the future of HCT Societies

•    APBMT perspective
     Shinichiro Okamoto (Japan) (President of APBMT)

14.42-15.00
Presidential Symposium: Design the future of HCT Societies

Q&A

15.00-15.30
Refreshment | Exhibition
15.30-15.55
Standardization and Accreditation in HSCT

•    Introduction
     Mickey Koh
     St.George's Hospital and Medical School, UK
     Udomsak Bunworasate
     Chulalongkorn Hospital/University, Thailand
•    Experience with FACT-JACIE accreditation at the Singapore General Hospital
     William Hwang (Singapore)

15.55-16.20
Standardization and Accreditation in HSCT

•    Importance of standardization and accreditation of CD34+ stem cell enumeration by flowcytometry for hematopoietic stem cell transplant (HSCT)
     David Ma (Australia)

16.20-17.00
Standardization and Accreditation in HSCT

Q&A

17.00-18.30
Dinner Symposium: Novartis

“CART treatment in hematologic malignancies: From clinical trials to clinical practice"
     Moderator:  Surapol Issaragrisil (Thailand)
•    Advances of CAR T in NHL
     Marion Subklewe (Germany)
•    A clinician’s view to treatment sequence and patient referral for CAR-T cell therapy in DLBCL
     Yok-Lam Kwong (Hong Kong)
•    CAR T cell Therapy for DLBCL in Singapore
     William Hwang (Singapore)

Meeting Room 2
Time Title
15.30-15.35
Novel cellular and gene therapy

Chair
Alok Srivastava
Christian Medical College, Vellore
Suradej Hongeng
Mahidol University, Thailand

15.35-16.00
Novel cellular and gene therapy

•    Update on gene therapy for thalassemia
     Philippe Leboulch (France)

16.00-16.25
Novel cellular and gene therapy

•    CRISPR based gene therapy
     Natee Jearawiriyapaisarn (Thailand)

16.25-16.50
Novel cellular and gene therapy

•    Induced pluripotent stem cell derived CAR-T cell
     Hiroshi Kawamoto (Japan)

COMMITTEES

APBMT Executive Board

Chair Shinichiro Okamoto (Japan)
Vice-Chair Alok Srivastava (India)
Members David D. Ma (Australia)
He Huang (China)
Amir Ali Hamidieh (Iran)
Jong Wook Lee (Korea)
William YK Hwang (Singapore)

APBMT 2021 Organizing Committee

Chair Shinichiro Okamoto (Japan)
Vice-Chair Alok Srivastava (India)
Advisors Saengsuree Jootar
Surapol Issaragrisil
Tanin Intragumtornchai
Ponlapat Rojnuckarin
President Artit Ungkanont
Chair of Scientific Program Suradej Hongeng
Co-Chair of Scientific Program Udomsak Bunworasate
Secretary-General 1 Adisak Tantiworawit
Secretary-General 2 Usanarat Anurathapan
Members Ekapun Karoopongse
Kanhatai Chiengthong
Kannadit Prayongratana
Kitsada Wudhikarn
Kleebsabai Sanpakit
Oytip Na Thalang
Pimjai Niparuck
Piya Rujkityanont
Vandee Ningsanond

Speakers

Usanarat Anurathapan

Ramathibodi Hospital, Mahidol University Bangkok, Thailand

Division of Hematology and Oncology Department of Pediatrics

Japp J. Boelens

Transplantation and Cellular Therapy Center Department of Pediatrics Memorial Sloan Kettering Cancer Center New York, NY, USA

Nelson Chao

Division of Hematologic Malignancies and Cellular Therapy Department of Medicine, Duke University School of Medicine Durham, North Carolina, USA

Godfrey Chi-Fung Chan

Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital & HKU-Shenzhen Hospital, The University of Hong Kong, Hong Kong

Sharat Damodar

The Bone Marrow Transplant Unit Narayana Health City Mazumdar Shaw Medical Center Bangalore, Karnataka, India

Stella Davies

Division of Bone Marrow Transplantation and Immune Defficiency Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio, USA

Juan Du

The Second Military Medical University Shanghai, P.R. China

Department of Hematology The Myeloma & Lymphoma Center Shanghai Changzheng Hospital

David Gottlieb

Westmead Clinical School The Westmead Institute for Medical Research – BMT University of Sydney, Australia

Hildegard Greinix

Waehringer Guertel, Vienna, Austria

Department of Medicine I Bone Marrow Transplantation Unit University of Vienna

Amir Ali Hamidieh

Tehran University of Medical Sciences Tehran, Iran

Pediatric Stem Cell Transplant Department Children’s Medical Center

Rupert Handgretinger

Department of Hematology/Oncology Children’s University Hospital Tubingen Germany

Suradej Hongeng

Ramathibodi Hospital, Mahidol University Bangkok, Thailand

Division of Hematology and Oncology Department of Pediatrics

William Hwang

National Cancer Centre Singapore

Yoshihiro Inamoto

Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo, Japan

Natee Jearawiriyapaisarn

Thalassemia Research Center Institute of Molecular Biosciences Mahidol University, Nakhon Pathom 73170, Thailand

Nutcharee Jungvanichar

Chief Nursing Officer Bumrungrad International Hospital Bangkok, Thailand

Hiroshi Kawamoto

Laboratory of Immunology Institute for Frontier Life and Medical Sciences (IFLMS) Kyoto University, Japan

Bor Sheng Ko

Department of Internal Medicine National Taiwan University Hospital (China, Taiwan)

Nicolaus Kröger

Department of Stem Cell Transplantation University Hospital Hamburg – Eppendorf Hamburg, Germany

Philippe Leboulch

Department of Medicine Brigham and Women’s Hospital 75 Francis St., Boston, MA 02115, USA

Pamela Lee

Department of Paediatrics & Adolescent Medicine Queen Mary Hospital, The University of Hong Kong Hong Kong

John E. Levine

The Mount Sinai School of Medicine Director of BMT Clinical Research New York, USA

Francesca Lorraine Lim

Department of Haematology Singapore General Hospital Singapore

David Ma

St.Vincent’s Clinical School University of New South Wales, Australia

Lt.Gen.Velu Nair

Internal Medicine, Clinical Hematology & Bone Marrow Transplant Armed Forces Medical Service, India

Shinichro Okamoto

Division of Hematology Department of Medicine Keio University of Medicine Tokyo, Japan

Vivek Roy

Division of Hematology/Oncology Department of Internal Medicine Mayo Clinic Jacksonville Jacksonville, Florida, 32224 USA

Matthew Porteus

Institute of Stem Cell Biology & Regenerative Medicine Department of Pediatrics, Division of Hematology/Oncology and Human Gene Therapy Stanford School of Medicine USA

Ho Ying Shi

Block 7 Level 2 Haematology Pharmacy Singapore General Hospital Singapore

John A. Snowden

Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, Sheffield, UK

Shui Yen Soh

Paediatric Haematology/Oncology Service KK Women's and Children's Hospital (KKH), Singapore.

Alok Srivastava

Department of Haematology Christian Medical College, Vellore, India

Takanori Teshima

Department of Hematology Director, Hematology and BMT program Hokkaido University, Japan

Dr.Trai Tharnpanich

Department of Pharmacy Practice, Chulalongkorn University, 254, Phayathai Road, Pathumwan, Bangkok 10330 Thailand

Naoyuki Uchida

Department of Hematology Toranomon Hospital Tokyo 105‐0001, Japan.

Daniel Weisdorf

Division of Hematology, Oncology and Transplantation University of Minnesota, Minneapolis, USA

Kitsada Wudhikarn

Division of Hematology Department of Medicine King Chulalongkorn Memorial Hospital Chulalongkorn University, Bangkok, Thailand

Lim Yan Yin

Nurse Manager the Children’s Cancer Centre KK Women’s and Children’s Hospital Singapore

Bo Yu

Deputy Chief Pharmacist Department of Pharmacy, Shanghai Tongren Hospital 1111 Xian-Xia Road, Shanghai 200032; P.R. China

Robert Zeiser

Hematology and Oncology University Medical Center Freiburg Freiburg, Germany